Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: OBSERVATIONAL
Official Title: A Multi-Center Unblinded Proof-of-Concept Study of DaxibotulinumtoxinA for Migraine: the 'EEG Paradigm'
Brief Summary:
This is a prospective, multi-center, unblinded study in patients with migraine (? 8 MMDs(monthly migraine days)/month) requiring preventive treatment.
Enrolled patients will receive DAXXIFY (DAX/Doxibutlinumtoxin A)administered subcutaneously per the EEG paradigm (injection pattern).
The safety and efficacy outcome measures will be assessed at selected dosing segments during the 24-week treatment phase as well as the Post Treatment (4 weeks).
There are 2 sites in the U.S. participating, where a total of 20 patients will be enrolled.